Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 61.45 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 96.01 | Oscillator | Sell |
| Williams %R (14) | -0.90 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.17 (Hist 0.17) | Oscillator | Strong Buy |
| Average Directional Index (14) | 15.29 (+DI 21.5 / -DI 14.1) | Trend | Neutral |
Current price $21.42
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Jul 30, 26 |
| EMA 20 | 20.39 | MA | Strong Buy |
| SMA 20 | 20.08 | MA | Strong Buy |
| EMA 50 | 19.99 | MA | Strong Buy |
| SMA 50 | 20.67 | MA | Strong Buy |
| SMA 200 | 15.78 | MA | Strong Buy |
| B. Riley Securities |
| maintain |
| Buy |
| Buy |
| Feb 27, 26 | Barrington Research | maintain | Outperform | Outperform |
| Jan 9, 26 | Barrington Research | maintain | Outperform | Outperform |
| Nov 6, 25 | Barrington Research | maintain | Outperform | Outperform |
| Sep 23, 25 | Barrington Research | maintain | Outperform | Outperform |
| Jul 31, 25 | Barrington Research | maintain | Outperform | Outperform |
| May 12, 25 | Barrington Research | maintain | Outperform | Outperform |
| Mar 13, 25 | Barrington Research | maintain | Outperform | Outperform |
| Nov 1, 24 | Barrington Research | maintain | Outperform | Outperform |
FY2023 · 10-K disclosure
FY2025 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 144 | Aug 7, 2026 | 2026-08-07 17:28:50 | View |
| 4 | Aug 5, 2026 | 2026-08-05 16:30:12 | View |
| SC 13G/A | Jul 31, 2026 | 2026-07-31 09:56:37 | View |
| S-8 | Jul 29, 2026 | 2026-07-29 16:20:27 | View |
| 10-Q | Jul 29, 2026 | 2026-07-29 16:09:26 | View |
| 8-K | Jul 29, 2026 | 2026-07-29 07:20:33 | View |
| SC 13G/A | Jul 17, 2026 | 2026-07-17 11:33:02 | View |
| 8-K | Jul 14, 2026 | 2026-07-14 17:00:16 | View |
| 4 | Jun 23, 2026 | 2026-06-23 16:30:19 | View |
| 4 | Jun 23, 2026 | 2026-06-23 16:30:14 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 4, 26 | Fischetti Gary P | director | P-Purchase | 1,000 @ $20.32 | $20.32K |
| Aug 3, 26 | Fischetti Gary P | director | P-Purchase | 1,000 @ $20.75 | $20.75K |
| Jun 18, 26 | Fischetti Gary P | director | A-Award | 10,402 | — |
| Jun 18, 26 | Henneman John B Iii | director | A-Award | 10,402 | — |
| Jun 18, 26 | Richard Stephen | director | A-Award | 10,402 | — |
| Jun 18, 26 | Capper Joseph H | director | A-Award | 10,402 | — |
| Jun 18, 26 | Conley Sheryl L | director | A-Award | 10,402 | — |
| Jun 3, 26 | Griffin Stephen D. | director, officer: President and CEO | M-Exempt | 12,840 | — |
Stock news · updated daily
BEDFORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2026 financial results before the opening of the market on Friday, November 6, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.
Anika Therapeutics (NASDAQ: ANIK - Get Free Report) and Xencor (NASDAQ: XNCR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings. Valuation and Earnings This table compares Anika Therapeutics
Corient Private Wealth LP bought a new stake in shares of Anika Therapeutics Inc. (NASDAQ: ANIK) during the undefined quarter, according to its most recent filing with the SEC. The firm bought 34,059 shares of the biotechnology company's stock, valued at approximately $498,000. Corient Private Wealth LP owned 0.25% of Anika Therapeutics as
Hsbc Holdings PLC purchased a new position in shares of Anika Therapeutics Inc. (NASDAQ: ANIK) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 50,105 shares of the biotechnology company's stock, valued at approximately $727,000. Hsbc Holdings PLC owned about 0.37% of
BTSG, ANIK and OPHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 26th, 2026.
Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 29, 2026 | 0.03 | 0.42 | Beat 1300.0% | $32.61M |
| Apr 29, 2026 | -0.07 | 0.27 | Beat 485.7% | $29.61M |
| Feb 26, 2026 | -0.13 | 0.31 | Beat 348.0% | $30.61M |
| Nov 5, 2025 | 0.02 | 0.04 | Beat 100.0% | $27.82M |
| Jul 30, 2025 | -0.13 | -0.13 | Beat 0.0% | $28.22M |
| May 9, 2025 | 0.09 | -0.06 | Miss -166.7% | $26.17M |
TTM vs. 5-year historical average (annual ratios)
| Metric | ANIK | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -79.5x | 14.7x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 20.4x | EPS est. 1.05 | Discount |
| Price / Book | 2.1x | 1.5x | Elevated |
| Price / Sales | 2.4x | 2.7x | In line |
| EV / EBITDA | 99.8x | -11.9x | Discount |
| Return on equity | -2.7% | — | Weak |
| Gross margin | 62.2% | 61.7% | In line |
| Debt / Equity | 0.17 | 0.13 | Conservative |
| Piotroski / Altman Z | 5/9 | Z 5.28 | Safe zone |
Discounted cash flow model